Olumiant

Generic name: Baricitinib
Dosage form: tablet (1mg, 2mg, 4mg)

Usage of Olumiant

Olumiant (Baricitinib) tablets are used to treat rheumatoid arthritis, severe alopecia areata and COVID-19 in certain patients. These conditions may be caused by an overactive immune system causing inflammation. Olumiant works by blocking a specific protein (Janus kinase) that causes inflammation to help relieve the symptoms of these conditions. Olumiant is classified as a Janus kinase inhibitor (JAK inhibitor).

In rheumatoid arthritis, the immune system attacks healthy joint tissues causing the joint to be inflamed. Olumiant reduces inflammation in RA to help relieve pain, swelling, and tenderness of the joints.

In alopecia areata (AA), hair loss is caused by the immune system attacking the hair follicles, causing inflammation which interrupts hair growth. Olumiant blocks inflammation, which allows hair to regrow. Olumiant treats symptoms of alopecia areata, but it is not a cure, and if you stop taking the tablets, then your hair loss may return.

Olumiant side effects

Stop taking this medicine and get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Some people taking Olumiant have developed heart attacks, strokes, or serious blood clots. Stop taking this medicine and seek emergency medical attention if you have:

sudden shortness of breath;

chest pain or pressure that may spread to your jaw, shoulder, arms, or back;

nausea, vomiting, cold sweat;

a light-headed feeling, like you might pass out;

weakness on one side of your body;

slurred speech, drooping on one side of your mouth; or

pain, swelling, or redness in an arm or a leg.

Olumiant may cause serious side effects. Call your doctor at once if you have:

fever, chills, night sweats, constant tiredness;

wheezing, trouble breathing, severe or worsening cough;

increased urination, pain or burning when you urinate;

unexplained weight loss;

lumps in your neck, armpits, or groin;

signs of shingles - flu-like symptoms, tingly or painful blistering rash on one side of your body;

a hole (perforation) in your digestive tract - fever, severe stomach pain, diarrhea or changes in bowel habits; or

signs of hepatitis - loss of appetite, vomiting, stomach pain (upper right side), dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).

Common side effects of Olumiant may include:

cold sores, shingles;

nausea; or

cold symptoms such as stuffy nose, sneezing, sore throat.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Before taking Olumiant

Taking Olumiant can increase your risk of life-threatening medical problems, including serious infections, a hole or tear in your digestive tract, a heart attack or stroke, blood clots, or cancer. Tell your doctor if you've had:

a weak immune system or chronic infection (such as tuberculosis, shingles, HIV, or hepatitis);

any type of cancer;

kidney disease;

diverticulitis, an ulcer in your stomach or intestines;

heart problems;

a heart attack, stroke, or blood clot;

high cholesterol; or

if you've ever smoked.

Tell your doctor if you've been sick with signs of infection, such as fever, chills, muscle aches, cough, trouble breathing, skin sores, diarrhea, or painful urination.

Tell your doctor if you've had or been exposed to tuberculosis, or if you recently traveled. Some infections are more common in certain parts of the world, and you may have been exposed during travel.

Also tell your doctor if you have ever had:

liver disease (especially hepatitis B or C);

chronic lung disease;

diabetes; or

if you are scheduled to receive any vaccine.

Using this medicine may increase your risk of developing certain cancers, such as lymphoma or lung cancer. Ask your doctor about this risk.

Pregnancy

Tell your doctor if you are pregnant or plan to become pregnant. It is not known if this medicine will harm an unborn baby. If you become pregnant during treatment with Olumiant call Eli Lilly and Company at 1-800-545-5979 to report the pregnancy.

Breastfeeding

Tell your doctor if you are breastfeeding or plan to breastfeed. It is not known if this medicine passes into your breast milk. You should not breastfeed during treatment with Olumiant and for 4 days after the last dose. Talk to your healthcare provider about the best way to feed your baby during treatment with this medicine.

How to use Olumiant

Usual Adult Dose of Olumiant for Rheumatoid Arthritis:

Dose: 2 mg tablet once a day Comments: This drug may be used as monotherapy or in combination with methotrexate or other DMARDs. Use: For the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

Usual Adult Dose of Olumiant for Alopecia Areata:

Dose: 2 mg tablet once daily. Dose maybe increased to 4 mg once daily, if the response to treatment is not adequate. For patients with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider treating with 4 mg once daily. Reduce the dose to 2 mg once daily when an adequate response has been achieved. Use: For the treatment of adult patients with severe alopecia areata

Usual Adult Dose of Olumiant for COVID-19:

Dose: 4 mg tablet once a day Duration of therapy: 14 days or until hospital discharge, whichever is first. Use: For the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO.

Usual Pediatric Dose of Olumiant for COVID-19 (For investigational use only)

Dose: 2 years to less than 9 years: 2 mg orally once a day. 9 years and older: 4 mg orally once a day. Duration of therapy: 14 days or until hospital discharge, whichever is first. Use: For treatment of COVID-19 in hospitalized pediatric patients two years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Comments:

In July 2021, the US FDA expanded the Emergency Use Authorization (EUA) for Olumiant to allow the emergency use of this drug, with or without remdesivir, for treatment of suspected or laboratory cOnfirmed COVID-19 in hospitalized pediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or ECMO;

The optimal duration of therapy is unknown.

This drug is not authorized for patients younger than 2 years.

Warnings

Taking Olumiant may increase your risk of life-threatening medical problems including serious infections, a hole or tear in your digestive tract, a heart attack or stroke, blood clots, or cancer.

Tell your doctor if you have a weak immune system, diabetes, chronic lung disease, or an infection such as hepatitis, tuberculosis, shingles, or HIV. Also tell your doctor if you've ever had diverticulitis, an ulcer in your stomach or intestines, cancer, heart problems, or a history of smoking, heart attack, stroke, or blood clots.

Call your doctor right away if you have a fever, night sweats, constant tiredness, weight loss, stomach pain, diarrhea or changes in bowel habits, trouble breathing, wheezing, a severe cough, or lumps in your neck, armpits, or groin.

Seek emergency medical help if you have sudden shortness of breath, chest pain spreading to your neck or arms, nausea, severe dizziness, a cold sweat, weakness on one side of your body, slurred speech, or pain, redness, or swelling in an arm or leg.

What other drugs will affect Olumiant

Tell your doctor about all your other medicines, especially:

methotrexate (sometimes given with Olumiant;

probenecid;

steroid medicine such as prednisone or Dexamethasone;

NSAIDs (nonsteroidal anti-inflammatory drugs) - aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), Celecoxib, diclofenac, Indomethacin, Meloxicam, and others; or

other drugs to treat rheumatoid arthritis - abatacept, adalimumab, anakinra, azathioprine, Certolizumab, cyclosporine, etanercept, golimumab, Infliximab, rituximab, sarilumab, tocilizumab, baricitinib.

This list is not complete. Other drugs may affect Olumiant, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here. Click the link below for check for interactions with Olumiant.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.